{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:49Z","timestamp":1790346709829,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2015-DI-070"],"award-info":[{"award-number":["2015-DI-070"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jconrel.2021.02.035","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T15:55:04Z","timestamp":1614959704000},"page":"517-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11"],"prefix":"10.1016","volume":"332","author":[{"given":"Ana","family":"Mato-Berciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Maliandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Farrera-Sal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gimenez-Alejandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia M.","family":"Ginest\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Torres-Manjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Arias-Badia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Capell\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Cascallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bazan-Peregrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.02.035_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","article-title":"Advances in oncolytic adenovirus therapy for pancreatic cancer","volume":"434","author":"Nattress","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/biomedicines2010036","article-title":"Oncolytic adenoviruses in cancer treatment","volume":"2","author":"Alemany","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0020","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/v7112923","article-title":"Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications","volume":"7","author":"Uusi-Kerttula","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0025","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0030","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/annonc\/mdz247.037","article-title":"Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial","volume":"30","author":"Garcia-Carbonero","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0040","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/nnm.12.50","article-title":"Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer","volume":"7","author":"Green","year":"2012","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082716","article-title":"Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo","volume":"9","author":"Prill","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c110beed-3cac-48db-9039-ba4498d5db50","article-title":"Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses","volume":"7","author":"Bruder","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2016.07.004","article-title":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","volume":"237","author":"Rojas","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semcancer.2008.03.005","article-title":"Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan","volume":"18","author":"Tammi","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/2159-8290.CD-11-0136","article-title":"Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look","volume":"1","author":"Whatcott","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.17925\/EOH.2018.14.1.40","article-title":"More than a Gel \u2013 Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic cancer","volume":"14","author":"Thomas Seufferlein","year":"2018","journal-title":"Eur. Oncol. Haematol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0085","first-page":"107","article-title":"Breaking the barrier\u2014PEGylated RecombinantHuman Hyaluronidase (PEGPH20)\u2014a new therapeutic approach to the treatment of pancreatic ductal adenocarcinoma","volume":"13","author":"Hendifar","year":"2017","journal-title":"Oncol. Hematol. Rev."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0090","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rodriguez-Garcia","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0095","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1158\/1078-0432.CCR-15-1899","article-title":"The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma","volume":"22","author":"Martinez-Velez","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0100","article-title":"Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01","volume":"11","author":"Vera","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/mthe.2000.0227","article-title":"Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver","volume":"3","author":"Tao","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0115","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-08-0488","article-title":"Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus","volume":"68","author":"Shashkova","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0120","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.onc.1202118","article-title":"Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells","volume":"17","author":"Villanueva","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0125","doi-asserted-by":"crossref","first-page":"22700","DOI":"10.18632\/oncotarget.15169","article-title":"A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel","volume":"8","author":"Mato-Berciano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0130","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/ijc.28259","article-title":"Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells","volume":"133","author":"Vives","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/mt.2009.279","article-title":"Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor","volume":"18","author":"Xu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0140","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/gt.2009.103","article-title":"A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses","volume":"16","author":"Rojas","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0145","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0150","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.02.035_bb0155","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/CVI.00207-14","article-title":"Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors","volume":"21","author":"Teigler","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/cgt.2009.5","article-title":"An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector","volume":"16","author":"Lichtenstein","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0165","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2021.02.035_bb0170","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0175","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.79.4.1992-2000.2005","article-title":"Adenovirus protein VI mediates membrane disruption following capsid disassembly","volume":"79","author":"Wiethoff","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/annonc\/mdz244.021","article-title":"Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer","volume":"30","author":"Hidalgo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0185","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","article-title":"Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models","volume":"9","author":"Thompson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0190","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0195","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1021\/ac202978r","article-title":"Electrochemical sensing of aptamer-facilitated virus immunoshielding","volume":"84","author":"Labib","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2021.02.035_bb0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/hum.2007.017","article-title":"Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters","volume":"18","author":"Bortolanza","year":"2007","journal-title":"Hum. Gene Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:39:51Z","timestamp":1777509591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"alternative-id":["S0168365921001103"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}